CStone Pharmaceuticals
CStone developed sugemalimab, the first Chinese PD-L1 antibody approved in Europe, and brought pralsetinib, avapritinib and ivosidenib to China.
Overview
Sugemalimab (Cejemly) approved in China 2021 and the EU 2024; Greater China rights to pralsetinib, avapritinib and ivosidenib; pipeline of ADCs and a PD-L1 x VEGF x CTLA-4 trispecific. A capital-constrained example of the 2015 biotech wave that relied on in-licensing plus one internal asset.
Scorecard
All companies- approved products +24
- targets +8
- modalities +4
- regions +6
- registry trials +17
Sugemalimab is CStone's PD-L1 antibody, approved in China for first-line lung cancer with chemotherapy and after chemoradiotherapy in stage III disease, and the first China-developed PD-L1 antibody to win European approval.
Pralsetinib is the second selective RET pill for lung cancer, less used than selpercatinib after a change of owner and label.
Avapritinib is the first drug for GIST driven by the PDGFRA D842V mutation, which resists every other kinase inhibitor; it is also approved for systemic mastocytosis.
Ivosidenib is a pill that blocks the mutant IDH1 enzyme, approved in bile duct cancer and in leukaemia.
Pages like this
not linked directly; found by shared links- ProductOncomine Dx Target Test
Shares Pralsetinib, Ivosidenib.